Answers are grounded in this paper and cite their sources.
Additional sex combs‑like 1 (ASXL1) is a chromatin‑associated protein that functions as a transcriptional coregulator through interactions with histone‑modifying enzymes. Although it is well established as a tumor suppressor in hematologic malignancies, its role in solid tumors remains unclear. ASXL1 has been shown to repress the E2F transcription factor 1 (E2F1)‑Nmyc axis during murine lung development, suggesting a potential tumor‑suppressive role in lung cancer. In the present study, bromodomain‑containing protein 2 (BRD2), a member of the bromodomain and extra‑terminal (BET) protein family, was identified as a direct binding partner of ASXL1. Analysis of human datasets revealed that ASXL1 expression is significantly downregulated and is associated with poor overall survival in patients with non‑small cell lung cancer (NSCLC). MTT assays using three NSCLC cell lines showed a positive correlation between ASXL1 expression and sensitivity to BET inhibitors (BETis). Consistently, ASXL1‑depleted H1299 cells exhibited reduced sensitivity to BETis compared with control cells. Although pan‑BETis target multiple BET family members, including BRD3 and BRD4, it was found that BRD2 was selectively upregulated following BETi treatment, suggesting a potential compensatory role. Furthermore, ASXL1 enhanced BETi‑mediated repression of E2F1 transcriptional activity. Collectively, these findings demonstrated that ASXL1 modulates BETi sensitivity, at least in part, through its interaction with BRD2 and repression of E2F1, highlighting ASXL1 as a potential in vitro sensitivity marker and therapeutic target for overcoming BETi resistance in NSCLC.
No takes yet. Share an insight, caveat, or question.
Byun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: